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Effect of Time-of-Flight and Regularized
Reconstructions on Quantitative Measurements
and Qualitative Assessments in Newly
Diagnosed Prostate Cancer With
18F-Fluorocholine Dual Time Point PET/MRI
Spencer C. Behr, MD1, Brett J. Mollard, MD1,2, Jaewon Yang, PhD1,
Robert R. Flavell, MD, PhD1, Randall A. Hawkins, MD, PhD1,
and Youngho Seo, PhD1,3
Abstract
Recent technical advances in positron emission tomography/magnetic resonance imaging (PET/MRI) technology allow much
improved time-of-flight (TOF) and regularized iterative PET reconstruction regularized iterative reconstruction (RIR) algorithms.
We evaluated the effect of TOF and RIR on standardized uptake values (maximum and peak SUV [SUVmax and SUVpeak]) and their
metabolic tumor volume dependencies and visual image quality for 18F-fluorocholine PET/MRI in patients with newly diagnosed
prostate cancer. Fourteen patients were administered with 3 MBq/kg of 18F-fluorocholine and scanned dynamically for 30 minutes.
Positron emission tomography images were divided to early and late time points (1-6 minutes summed and 7-30 minutes
summed). The values of the different SUVs were documented for dominant PET-avid lesions, and metabolic tumor volume was
estimated using a 50% isocontour and SUV threshold of 2.5. Image quality was assessed via visual acuity scoring (VAS). We found
that incorporation of TOF or RIR increased lesion SUVs. The lesion to background ratio was not improved by TOF recon-
struction, while RIR improved the lesion to background ratio significantly (P < .05). The values of the different VAS were all
significantly higher (P < .05) for RIR images over TOF, RIR over non-TOF, and TOF over non-TOF. In conclusion, our data indicate
that TOF or RIR should be incorporated into current protocols when available.
Keywords
cancer detection imaging, novel imaging methods/agents for clinical studies, quantitation in molecular imaging, cancer imaging,
PET/MRI, prostate cancer
Introduction
Prostate cancer remains the most common cancer diagnosed in
men in the United States and is among the leading causes of
cancer-related mortality.1 Imaging continues to play an
increasing role in the evaluation of prostate cancer and sus-
pected cancer recurrence. Multiparametric prostate magnetic
resonance imaging (MRI) is the current diagnostic imaging
workhorse, although it is still undergoing continuous evolution
to overcome inherent limitations. For example, Muller et al
recently showed that the revised Prostate Imaging Reporting
and Data System (PI-RADS 2.0) provides moderately reprodu-
cible MRI scores similar to PI-RADS 1.0 for clinically relevant
prostate cancer.2 Newer experimental radiopharmaceuticals
have made positron emission tomography (PET) combined
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with computed tomography (CT) and MRI interesting research
subjects aimed at improving the diagnostic accuracy of prostate
cancer diagnosis.3-5
Combined with multiparametric prostate MRI, PET imaging
in PET/MRI is a natural extension of current prostate imaging
practice.6,7 Recent advancements in PET detector technology
also have made time-of-flight (TOF) imaging capability and its
associated TOF-enabled reconstruction, which is a standard
technology in modern PET/CT scanners, feasible in the clinical
PET/MRI setting. The TOF-enabled reconstruction (herein-
after, “TOF reconstruction” for simplicity) is known for
improved spatial resolution, contrast to noise ratio, and image
quality in PET/CT.8-13 The improved resolution for TOF recon-
struction, in comparison to that for non-TOF reconstruction (ie,
the reconstruction without the TOF feature), is primarily due to
faster convergence; thus at comparable iterations, TOF recon-
struction typically yields better spatial resolution than non-
TOF reconstruction does.
Further technological advance in TOF-PET, particularly the
use of solid-state photomultipliers instead of photomultiplier
tubes as the photodetector, made it possible for the TOF capa-
bility to be implemented even in a strong magnetic field, trans-
lating it into clinical PET/MRI systems as well.12,14-16
In addition to TOF reconstruction capability, a regularized
iterative reconstruction (RIR) algorithm has been clinically
implemented (Q.Clear; GE Healthcare, Waukesha, Wiscon-
sin).17-20 However, this regularized reconstruction algorithm
has not been available clinically for PET/MRI yet. Currently,
no literature exists examining the effect of TOF or regularized
reconstruction on standardized uptake values (SUVs), image
quality, or lesion conspicuity for PET/MR imaging of prostate
cancer. Also, there is no standard static acquisition protocol for
the clinically used prostate cancer PET radiopharmaceuticals
such as 11C-acetate, 18F-fluorocholine, and 68Ga-labelled
Glu-urea-Lys(Ahx)-HBED-CC (68Ga–HBED-CC).3-5,21 We
acquired our 18F-fluorocholine PET/MRI dynamically over 30
minutes, so that we could evaluate the performance of static acqui-
sitions by summing early and late imaging time (dual-time) points.
In this report, we compared effects of dual-time point ima-
ging and TOF and RIR techniques on lesion maximum and
peak SUV (SUVmax and SUVpeak), background pelvic mean
SUV (SUVmean), metabolic tumor volume estimated by PET
using a 50% isocontour boundary, visual image quality assess-
ment, and confidence in lesion detection in the evaluation of
newly diagnosed biopsy-proven high-risk prostate cancer with
non-TOF ordered subsets expectation maximization (OS-EM)
reconstruction.
Materials and Methods
Patient Cohort
From April 1, 2015, until October 30, 2015, 14 men (average
age of 62 years+ 7) diagnosed with biopsy-proven intermedi-
ate or high-grade prostate cancer characterized by preoperative
Cancer of the Prostate Risk Assessment (CAPRA) score22,23
(ie, CAPRA score  3) were evaluated with 18F-fluorocholine
PET/MRI of the pelvis in this institutional review board–
approved study. Dominant clinically relevant tumors with
Gleason score 3þ4/4þ3 or greater were evaluated. Prostatic
lesions were found in 12 patients, and a total of 17 tumors were
identified by 18F-fluorocholine PET/MRI for quantitative
analysis.
18F-Fluorocholine PET/MRI Protocol
Positron emission tomography imaging was performed imme-
diately following intravenous (IV) administration of 3 MBq/kg
of 18F-fluorocholine via a peripheral IV catheter after at least 4
hours of fasting for 30 minutes. Positron emission tomography
images were acquired on a TOF-PET/3-tesla MRI scanner
(SIGNA PET/MR; GE Healthcare) in 3-D acquisition mode
over the pelvis. 18F-fluorocholine uptake was recorded in list
mode and the list -mode data were replayed into 2 time points,
1 to 6 minutes summed and 7 to 30 minutes summed after
administration of the radiotracer. Based on the observation of
the tracer kinetics over 30 minutes from dynamic reconstruc-
tions of the entire 30 minutes,16 the early time duration (1-6
minutes), excluding the first minute of mostly blood pool
uptake, was determined since the rapid uptake of 18F-
fluorocholine reaches a plateau mostly around 5 to 6 minutes.
In addition, the late time duration (7-30 minutes), with at least a
minute gap from the early time point, was determined to cap-
ture accumulated activity after the radiotracer reached the pla-
teau. Reconstruction was performed in a matrix size of 128 
128 (voxel size ¼ 2.34  2.34  2.78 mm3) with other para-
meters: transverse field of view ¼ 300 mm, TOF-enabled and
TOF-disabled OS-EM algorithm with 28 subsets and 2 itera-
tions, 5-mm full-width at half-maximum postreconstruction
Gaussian filter and 1:4:1 axial filter for both TOF-enabled
reconstruction (“TOF reconstruction”), and TOF-disabled
reconstruction (“non-TOF reconstruction”). Finally, the RIR
algorithm was used for the same data sets with a regularization
parameter beta value of 350, 3 and 2 initial non-TOF regular-
ized and OS-EM iterations followed by 8 TOF regularized
iterations. A set of representative images using non-TOF, TOF,
and RIR algorithms for both time points (early and late) are
shown in Figure 1. The choice of reconstruction parameters
such as the number of iterations, the number of subsets, and
the sequence of non-TOF and TOF regularized iterations were
based on the vendor-default recommended parameters which
are commonly used at our center as well, not intended to be
optimized further by our own investigation. This way, we
assessed the image qualities from each reconstruction algo-
rithm as all of the readers using this imaging system would see.
Magnetic resonance imaging was performed simultaneously
during PET acquisition utilizing an endorectal coil. Standard
MR-based attenuation correction was applied using liver accel-
erated volume acquisition -flex MR images (repetition time
[TR] * 4 millisecond, echo time [TE]: 2.23 millisecond, flip
angle: 5 or 12 , partial Fourier: 70.3%, acquisition time: 18
seconds) with a standard body coil developed for PET/MRI
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(lower anterior array coil; GE Healthcare). Axial T2-weighted
with fat-saturation, axial diffusion-weighted imaging with b val-
ues ¼ 0, 50, 600, and 1350, axial apparent diffusion coefficient
maps, axial T1-weighted without and with fat saturation prior to
gadolinium-based contrast (gadobutrol) administration, dynamic
contrast-enhanced axial T1-weighted with fat saturation, and
MR spectroscopy pulse sequences were obtained. Washin and
washout curves were generated and mapped over the prostate.
For this investigation of comparing different PET reconstruc-
tions, we did not use any of these MR images, by the way.
Positron Emission Tomography Image Analyses
All reconstructed PET images were reviewed independently by
2 board-certified radiologists with training in nuclear medicine.
Maximum and peak SUVs24 (SUVmax and SUVpeak) were
documented for dominant suspicious prostate lesions and
SUVmean was obtained of the pelvis (ischium) as background.
All SUVs were measured on OsiriX (Pixmeo, Bernex, Switzer-
land). Metabolic tumor volume by PET was measured using a
50% isocontour and an SUV threshold of 2.5 to determine
tumor boundaries and calculate the encompassed volume uti-
lizing OsiriX. For quantitative analysis, we first examined the
difference in SUV measurements from different reconstruction
for early (1-6 minutes) and late time (7-30 minutes) point
data by taking the ratios of lesion SUVmax and SUVpeak from
TOF and RIR reconstructions to those from non-TOF
reconstructions.
Since an RIR reconstruction with a sufficiently large num-
ber of iterations results in a higher spatial resolution than cor-
responding TOF and non-TOF reconstructions, and a TOF
reconstruction also converges faster than non-TOF reconstruc-
tion with the same number of iterations for both, the relative
SUVs are expected to depend on the size of lesion where SUVs
were derived. It is important to note that for RIR reconstruc-
tion, the number of iterations should be sufficiently large as in
our case (3 and 2 initial non-TOF regularized and OS-EM
iterations followed by 8 TOF regularized iterations) because
RIR reconstruction can provide poorly converged images (ie,
smoother images) accompanied by spatial resolution degrada-
tion. Hence, we also examined the lesion volume dependencies
of these ratios by generating scatter plots of the ratios over the
metabolic tumor volumes.
Then, we compared the lesion to background (target to
background ratio or TBR) and lesion to blood ratios (target
to blood or TBlood) from different reconstructions and differ-
ent time point data to illustrate any perceived visual contrast of
lesion to background with regard to different reconstruction
and different time points. After this step, in order to depict how
different reconstructions and different time points affect TBR
and TBlood, we took ratios of TBRs and TBlood of TOF to
those of non-TOF and ratios of TBRs and TBlood of RIR to
those of non-TOF reconstructions for both time point (early and
late) data sets. Finally, image quality was subjectively assessed
using visual acuity scoring (VAS), ranking image quality on a
scale of 1 to 100. The paired 2-tailed t test was used to compare
the SUV ratios, TBRs, TBloods, and VAS’s to investigate
whether the difference is statistically significant.
Results
Standardized Uptake Values Consistency
Relative lesion SUVs for TOF and RIR data sets to non-TOF
data sets (SUVTOF/SUVnon-TOF, SUVRIR/SUVnon-TOF) are as
follows. The ratios of SUVmax for TOF to that for non-TOF
were 1.14 + 0.29 (range: 1.00-1.72) for the 1- to 6-minute
uptake period and 1.17 + 0.13 (range: 1.02-1.45) for the 7-
to 30-minute uptake period, respectively. The ratios of SUVmax
for RIR to that for non-TOF were 1.56 + 0.42 (range: 1.20-
2.64) for the 1- to 6-minute uptake period and 1.26 + 0.42
(range: 1.00-2.43) for the 7- to 30-minute uptake period,
respectively. The ratios of SUVpeak for TOF to that for non-
TOF were 1.14+ 0.13 (range: 0.98-1.49) for the 1- to 6-minute
uptake period and 1.11+ 0.10 (range: 0.93-1.30) for the 7- to
30-minute uptake period, respectively. The ratios of SUVpeak
for RIR to that for non-TOF were 1.30 + 0.21 (range: 0.97-
1.96) for the 1- to 6-minute uptake period and 1.06 + 0.20
(range: 0.70-1.52) for the 7- to 30-minute uptake period,
respectively. Figure 2 shows the SUV ratios for all reconstruc-
tions and at the 2 time points in 1 plot to depict the relative
consistencies of SUV measurements. The relative lesion SUVs
of RIR to non-TOF reconstructions are significantly larger than
those of TOF to non-TOF in the early time point images (P <
.05); however, the relative lesion SUVs of RIR to non-TOF
reconstruction do not show statistically significant differences
to those of TOF to non-TOF reconstruction in the late time
point images (P > .05).
Standardized Uptake Values Dependence on
Metabolic Volume
Using the metabolic volume average from 2 methods (50%
isocontour and 2.5 SUV threshold) measured for the data sets
reconstructed with TOF and RIR, scatter plots were generated
to show the ratios of lesion SUVs (SUVmax and SUVpeak) of
TOF to non-TOF and RIR to non-TOF reconstructions,
Figure 1. A representative set of images reconstructed using non-
TOF, TOF, and RIR algorithms. Axial images are shown in the top row,
and maximum intensity projection (MIP) images are shown in the
bottom row. From left to right: non-TOF, TOF, and RIR images from
the early (1-6 minute) time point data set. Non-TOF, TOF, and RIR
images from the late (7-30 minute) time point data set. RIR indicates
regularized iterative reconstruction; TOF, time-of-flight.
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respectively (Figure 3). These scatter plots clearly show the
dependence on the measured volume for the relative SUVs.
The smaller the metabolic tumor volume is, the larger relative
SUVs were observed for both TOF and RIR reconstructions
over non-TOF reconstructions. In addition, for the RIR recon-
structions as they are expected to have better convergences
than both TOF and non-TOF reconstructions, the difference in
SUVs is greater in small metabolic volumes. These data also
show that when the metabolic tumor size reaches approxi-
mately 4 mL, the relative SUVs do not show increase over
the volume.
Lesion to Background and Lesion to Blood
Relative TBRs for TOF and RIR data sets to non-TOF data sets
(TBRTOF/TBRnon-TOF, TBRRIR/TBRnon-TOF) and relative
TBloods for TOF and RIR data sets to non-TOF data sets
(TBloodTOF/TBloodnon-TOF, TBloodRIR/TBloodnon-TOF) are as
follows. The ratios of TBR for TOF to that for non-TOF were
0.86 + 0.25 (range: 0.59-1.47) for the 1- to 6-minute uptake
period and 0.85 + 0.13 (range: 0.54-1.02) for the 7- to 30-
minute uptake period, respectively. The ratios of TBR for RIR
to that for non-TOF were 1.03 + 0.35 (range: 0.59-1.89) for
the 1- to 6-minute uptake period and 1.04+ 0.31 (range: 0.64-
1.58) for the 7- to 30-minute uptake period, respectively. The
ratios of TBlood for TOF to that for non-TOF were 0.96 +
0.14 (range: 0.75-1.19) for the 1- to 6-minute uptake period and
1.07+ 0.12 (range: 0.83-1.20) for the 7- to 30-minute uptake
period, respectively. The ratios of TBlood for RIR to that for
non-TOF were 1.57+ 0.44 (range: 0.78-2.37) for the 1- to 6-
minute uptake period and 1.20 + 0.33 (range: 0.77-2.01) for
the 7- to 30-minute uptake period, respectively. Figure 4 shows
the TBRs and TBloods for all reconstructions and at the 2 time
points in 1 plot to depict the changes and consistencies of lesion
to background and lesion to blood contrast. The relative TBRs
and TBloods of RIR over non-TOF are all larger than those of
TOF over non-TOF reconstructions at all time points. The
differences are all statistically significant (P < .05) except for
the difference between TBlood of RIR over non-TOF and
TBlood of TOF over non-TOF for the 7- to 30-minute data set
(P > .05).
Image Quality
Mean VAS was 57.6, 68.1, and 80.9 for non-TOF, TOF, and
RIR reconstructions, respectively for one of the radiologists,
Figure 3. Scatter plots of SUVs (max and peak) measured from data sets reconstructed using the TOF and RIR algorithms over SUVs measured
from data sets reconstructed using the non-TOF algorithm. RIR indicates regularized iterative reconstruction; SUVs, standardized uptake values;
TOF, time-of-flight.
Figure 2. Ratios of SUVmax and SUVpeak in lesions of TOF to non-
TOF and RIR to non-TOF reconstructions for the early (1-6 minutes
summed) and late (7-30 minutes summed) data sets. RIR indicates
regularized iterative reconstruction; SUV, standardized uptake values;
TOF, time-of-flight.
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and 58.8, 70.9, and 78.6, respectively, for the other radiologist for
the 1- to 6-minute acquisition data sets and 48.4, 53.4, and 76.5,
respectively, for one of the radiologists and 55.1, 68.4, and 75.4,
respectively, for the other radiologist for the 7- to 30-minute acqui-
sition data sets. The VAS was significantly higher for RIR recon-
structed data sets overTOF reconstructed data sets, TOFover non-
TOF, andRIRoverTOF for both timepoint data sets (P< .05). The
VASwasbetter for the early timepoint data (1-6minutes summed)
than the late time point data (7-30minutes summed) for non-TOF
reconstructions with statistical significance (P < .05) for both
readers; however, for TOF and RIR reconstructions, there was
no statistically significant difference (P > .05) between the 2 time
point data. Figure 5 shows box plots of VAS between data sets for
the 2 radiologists who performed VAS.
Discussion
Addition of TOF and RIR capability for image reconstruction
to 18F-fluorocholine PET/MRI increases SUVmax and SUVpeak
for both 1- to 6-minute and 7- to 30-minute acquisition data sets
over corresponding non-TOF data sets. The reason for this
difference is primarily because of improved spatial resolution
of TOF-enabled PET reconstruction when the same number of
iterations was used in our case and improved spatial resolution
of RIR PET reconstruction when a sufficient number of itera-
tions were performed. Consistent with a modest increase in
SUVmax and SUVpeak using TOF and RIR reconstructions,
image quality assessed by VAS also showed significant
improvement when TOF and regularized reconstructions were
used over images generated by conventional non-TOF recon-
structions. Some of these findings are in keeping with the pre-
viously reported benefits of TOF for PET/CT, including
increased signal and contrast to noise ratio, improved lesion
detectability, and detecting low contrast lesions in a noisy
background by increasing sensitivity and reducing image
noise.9,25-27 These benefits of TOF should allow for a decrease
in patient dose, acquisition time, or both as demonstrated fol-
lowing the addition of TOF to PET/CT.28 Unlike extensive
literature reports on the benefits of TOF reconstructions,
reports of regularized reconstruction’s benefits in quantitative
measurements and qualitative visual image assessment using
clinical data are scarce; however, our findings are consistent
with a few case reports in the literature.19,29
There are several limitations inherent to this study, includ-
ing small sample size and retrospective nature. Also, our
assessment was only confined to prostate 18F-fluorocholine
PET/MRI data sets, while the TOF and RIR algorithms can
be used for any other PET data sets when these algorithms are
available. Effects of TOF and RIR on clinical outcomes and
sensitivity of detecting intermediate or high-grade prostate can-
cer were not assessed. While radiotracer uptake was noted in all
Figure 5. Box plots of VAS performed by 2 board-certified radiologists. VAS indicates visual acuity scoring.
Figure 4. Target-to-background (TBR, lesion-to-ischium) and target-
to-blood (TBlood, lesion-to-blood pool) differences are shown as ratios
of TBRs andTBloods ofTOFdata sets to non-TOFdata sets andRIRdata
sets to non-TOF data sets for both early and late time point images. RIR
indicates regularized iterative reconstruction; TOF, time-of-flight.
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lesions, uptake pattern in nontarget lesions, such as benign
prostatic hypertrophy nodules, was not assessed. It is possible
that the increase in SUVmax and SUVpeak with TOF and RIR
could translate into an increased sensitivity in detecting small
lesions, though this topic requires further investigation.
Conclusion
Our data strongly suggest that incorporation of TOF and RIR
algorithms should be used when available for prostate 18F-
fluorocholine PET/MRI. In particular, RIR algorithm outper-
formed TOF algorithm without regularization when compared
side-by-side in terms of image quality assessment for our data
sets. Hence, in order to fully capture the promise of RIR algo-
rithms, further investigation on the performance of RIR includ-
ing TOF for other PET imaging scenarios is warranted.
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